WO2004000313A3 - Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 - Google Patents

Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 Download PDF

Info

Publication number
WO2004000313A3
WO2004000313A3 PCT/FR2003/001924 FR0301924W WO2004000313A3 WO 2004000313 A3 WO2004000313 A3 WO 2004000313A3 FR 0301924 W FR0301924 W FR 0301924W WO 2004000313 A3 WO2004000313 A3 WO 2004000313A3
Authority
WO
WIPO (PCT)
Prior art keywords
lateral sclerosis
amyotrophic lateral
pgc
activity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/001924
Other languages
English (en)
Other versions
WO2004000313A2 (fr
Inventor
Fabien Schweighoffer
Annelies Resink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0207783A external-priority patent/FR2841141A1/fr
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Priority to AU2003260618A priority Critical patent/AU2003260618A1/en
Publication of WO2004000313A2 publication Critical patent/WO2004000313A2/fr
Publication of WO2004000313A3 publication Critical patent/WO2004000313A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne le domaine de la biologie, de la génétique et de la médecine. Elle concerne notamment de nouvelles méthodes pour le traitement (ou la prise en charge) de la sclérose latérale amyotrophique. L'invention concerne également des méthodes pour l'identification ou le criblage de composés actifs dans cette pathologie. L'invention concerne également les composés, gènes, cellules, plasmides ou compositions utiles pour la mise en oeuvre des méthodes ci-dessus. L'invention décrit notamment le rôle de PGC1 dans cette pathologie et son utilisation comme cible thérapeutique.
PCT/FR2003/001924 2002-06-24 2003-06-23 Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1 Ceased WO2004000313A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003260618A AU2003260618A1 (en) 2002-06-24 2003-06-23 Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0207783A FR2841141A1 (fr) 2002-06-24 2002-06-24 Nouvelles approches therapeutiques de la sclerose lateral amyotrophique
FR02/07783 2002-06-24
US39326102P 2002-07-02 2002-07-02
US60/393,261 2002-07-02

Publications (2)

Publication Number Publication Date
WO2004000313A2 WO2004000313A2 (fr) 2003-12-31
WO2004000313A3 true WO2004000313A3 (fr) 2004-04-22

Family

ID=30001929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/001924 Ceased WO2004000313A2 (fr) 2002-06-24 2003-06-23 Traitement de la sclerose laterale amyotrophique avec des composes modulateurs de l’activite de pgc-1

Country Status (2)

Country Link
AU (1) AU2003260618A1 (fr)
WO (1) WO2004000313A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579093A1 (fr) * 2004-09-03 2006-03-09 Dana-Farber Cancer Institute, Inc. Compositions et procedes de modulation de pgc-1.alpha. pour le traitement de maladies et de troubles neurologiques
WO2011074690A1 (fr) * 2009-12-14 2011-06-23 Kyoto University Composition pharmaceutique destinée à la prévention ou au traitement de la sclérose latérale amyotrophique
CA2911040C (fr) 2012-05-02 2021-11-16 Georgetown University Traitement d'une synucleinopathie au moyen d'inhibiteurs de la tyrosine kinase
CN105636582A (zh) * 2013-09-18 2016-06-01 乔治城大学 用非诺贝特及其类似物治疗神经退行性疾病
CN120040470A (zh) 2018-11-20 2025-05-27 乔治敦大学 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2001035096A2 (fr) * 1999-11-10 2001-05-17 Mitokor Modulation de la masse et de la fonction mitochondriales permettant de traiter des maladies, et de cibler et de decouvrir des medicaments

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058473A2 (fr) * 1999-03-31 2000-10-05 Curagen Corporation Acides nucleiques comprenant des phases de lecture ouverte codant des polypeptides; «orfx»
WO2001035096A2 (fr) * 1999-11-10 2001-05-17 Mitokor Modulation de la masse et de la fonction mitochondriales permettant de traiter des maladies, et de cibler et de decouvrir des medicaments

Also Published As

Publication number Publication date
WO2004000313A2 (fr) 2003-12-31
AU2003260618A8 (en) 2004-01-06
AU2003260618A1 (en) 2004-01-06

Similar Documents

Publication Publication Date Title
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
UA84025C2 (en) Normal;heading 1;heading 2;2-(QUINOXALIN-5-YLSULFONYLAMINO)-BENZAMIDE COMPOUNDS AS CCK2 MODULATORS
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
WO2003016475A3 (fr) Sequences d'acides nucleiques et d'acides amines intervenant dans la douleur
WO2008057459A3 (fr) Antagonistes de pcsk9
WO2008057457A3 (fr) Antagonistes de pcsk9
WO2008057458A3 (fr) Antagonistes de pcsk9
WO2004047760A3 (fr) Nouveaux composes chimiques
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
IL157652A (en) Metalloproteinase inhibitors, compositions comprising them and uses thereof for the preparation of medicaments for treating diseases or conditions mediated by metalloproteinase enzymes
AU2003234529A1 (en) Glp-1 gene delivery for the treatment of type 2 diabetes
AU2003221745A1 (en) rAAV VECTOR-BASED COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MAMMALIAN DISEASES
TR200500221T2 (tr) Farmasötik Maddeler Olarak Bisiklik Amino Asitler
AU2002349352A1 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
SG156650A1 (en) Thienopyrimidines useful as aurora kinase inhibitors
WO2003016563A3 (fr) Cible moleculaire de la neurotoxicite
WO2007025988A3 (fr) Formulations liquides d'hormone de croissance pegylee
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2003010291A3 (fr) Traitement de troubles concernant les cellules immunitaires et les cellules b
WO2005046587A3 (fr) Preparation et composition de proteines d'inhibiteur inter-alpha a partir du plasma humain, a usage therapeutique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP